Shares of Tilray Inc (NASDAQ:TLRY - Get Free Report) were up 0.8% on Thursday . The stock traded as high as $2.51 and last traded at $2.50. Approximately 16,859,926 shares were traded during trading, a decline of 33% from the average daily volume of 25,174,572 shares. The stock had previously closed at $2.48.
Tilray Stock Down 0.4 %
The company has a market cap of $1.83 billion, a price-to-earnings ratio of -1.11 and a beta of 2.30. The company has a quick ratio of 0.99, a current ratio of 1.63 and a debt-to-equity ratio of 0.11. The stock has a fifty day moving average price of $1.88 and a two-hundred day moving average price of $2.00.
Insider Buying and Selling at Tilray
In other news, CEO Irwin D. Simon acquired 53,700 shares of the stock in a transaction dated Friday, January 12th. The stock was bought at an average price of $1.88 per share, with a total value of $100,956.00. Following the completion of the purchase, the chief executive officer now directly owns 2,033,058 shares of the company's stock, valued at approximately $3,822,149.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Tilray news, CEO Irwin D. Simon purchased 53,700 shares of the business's stock in a transaction dated Friday, January 12th. The shares were bought at an average price of $1.88 per share, for a total transaction of $100,956.00. Following the completion of the acquisition, the chief executive officer now owns 2,033,058 shares in the company, valued at $3,822,149.04. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Carl A. Merton acquired 20,000 shares of the firm's stock in a transaction that occurred on Friday, January 12th. The stock was bought at an average price of $1.87 per share, with a total value of $37,400.00. Following the completion of the acquisition, the chief financial officer now directly owns 20,000 shares of the company's stock, valued at $37,400. The disclosure for this purchase can be found here. Over the last three months, insiders bought 96,300 shares of company stock worth $183,210. 0.68% of the stock is currently owned by insiders.
Institutional Trading of Tilray
Several institutional investors have recently added to or reduced their stakes in the stock. Mercer Global Advisors Inc. ADV boosted its stake in shares of Tilray by 10.0% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 28,072 shares of the company's stock valued at $77,000 after purchasing an additional 2,550 shares during the last quarter. Rhumbline Advisers boosted its holdings in Tilray by 20.4% in the second quarter. Rhumbline Advisers now owns 15,464 shares of the company's stock worth $48,000 after acquiring an additional 2,623 shares in the last quarter. CreativeOne Wealth LLC lifted its stake in Tilray by 8.0% during the 3rd quarter. CreativeOne Wealth LLC now owns 40,591 shares of the company's stock valued at $112,000 after acquiring an additional 2,994 shares in the last quarter. State of Wyoming boosted its holdings in Tilray by 17.0% during the 4th quarter. State of Wyoming now owns 24,561 shares of the company's stock worth $66,000 after acquiring an additional 3,564 shares during the last quarter. Finally, Private Advisor Group LLC grew its stake in shares of Tilray by 6.1% in the 2nd quarter. Private Advisor Group LLC now owns 73,033 shares of the company's stock worth $114,000 after acquiring an additional 4,177 shares in the last quarter. 9.35% of the stock is currently owned by institutional investors.
About Tilray
(
Get Free Report)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Read More
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
